Investor Overview
News
- Kindred Biosciences Announces Half-Life Extension Technology for Canine AntibodiesJanuary 8, 2020 4:02 PM EST
- Kindred Biosciences Unveils Positive Results from Pilot Study of its Interleukin-4R Monoclonal Antibody Being Developed for the Treatment of Atopic Dermatitis in DogsDecember 16, 2019 8:02 AM EST
- Kindred Biosciences Announces European Commission Approval of Mirataz® 20 mg/g Transdermal Ointment for Cats Experiencing Poor Appetite and Weight LossDecember 12, 2019 9:05 AM EST
Events
- Wednesday, January 8, 2020 4:30 PM EST
- Thursday, November 21, 2019
- Tuesday, November 19, 2019 from 10:20 AM to 10:50 AM EST
|
||||||||||||||||
KindredBio proudly supports
Rabies Free Africa
Investor Overview
KindredBio is focused on bringing breakthrough human products and innovative new technologies to veterinary medicine to address unmet clinical needs and provide benefits to animal co...
Stock Information
News
Kindred Biosciences Announces Half-Life Extension Technology for Canine Antibodies
January 8, 2020
- Positive results from canine pharmacokinetic study demonstrate up to three-fold...
Kindred Biosciences Unveils Positive Results from Pilot Study of its Interleukin-4R Monoclonal Antibody Being Developed for the Treatment of Atopic Dermatitis in Dogs
December 16, 2019
SAN FRANCISCO , Dec. 16, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ:...
Kindred Biosciences Announces European Commission Approval of Mirataz® 20 mg/g Transdermal Ointment for Cats Experiencing Poor Appetite and Weight Loss
December 12, 2019
- Mirataz is the first and only medication approved in the European Union to trea...